Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  C-Rad AB (publ)    CRAD B   SE0002016352

C-RAD AB (PUBL)

(CRAD B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

C Rad : Shanghai Proton and Heavy Ion Hospital decides for C-RAD SIGRT solution

09/28/2020 | 09:03am EST

C-RAD announced today that Shanghai Proton and Heavy Ion Hospital (SPHIC) has chosen C-RAD as their supplier to implement the surface guidance program based on Catalyst™ and Sentinel™ 4DCT technology.

SPHIC is one of the leading cancer treatment centers in China and the first Heavy Ion and Proton Center in the country. The site is equipped with the Siemens IONTRIS system and has in total four treatment rooms. Since 2015 very specialized treatments can be offered to the patients. Beside the IONTRIS system, the site is offering cancer treatments with two photon treatment systems. The Chinese market for advanced treatment systems is growing rapidly.

The first treatment room and two CT rooms are expected to be equipped with Catalyst system™ before the end of this year.

"We are excited about the decision and the opportunity for C-RAD to work with this high-profiled cancer center in China. The fact that a major cancer center in China now decided to adopt our SIGRT solution confirms our firm belief, that the C-RAD technology is on its way to become a true standard of care in advanced radiation therapy", says Tim Thurn, CEO of C-RAD.

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - the Catalyst PT, based on the patented Catalyst technology and software. The system allows a seamless integration to support the clinical workflow by improving patient positioning accuracy and operational efficiency.

Kurt Wang, President C-RAD China, says "This is an important milestone for C-RAD in China. I am so enthusiastic to work with the team at SPHIC and to build up a clinical training center for other proton customers. The cooperation will promote the C-RAD SIGRT solution to become standard of care also for proton treatments. I believe together with the SPHIC team C-RAD can make a difference for the society and especially for the patients that will benefit from the treatments at this site."

It is the objective to develop the site to become a reference site for C-RAD and to be able to show the potential of the technology within high precision radiation therapy.

The installation is expected to take place before the end of this year.

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ OMX Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

https://news.cision.com/c-rad/r/shanghai-proton-and-heavy-ion-hospital-decides-for-c-rad-sigrt-solution,c3204118

https://mb.cision.com/Main/13008/3204118/1311718.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about C-RAD AB (PUBL)
01/18C RAD : Web Presentation Year-end Report 2020
AQ
2020C RAD : receives order for proton cancer treatment centers in the US
AQ
2020C RAD : Shenzhen proton therapy treatment center selects C-RAD Catalyst™ s..
AQ
2020C RAD : 15 percent growth in order intake and record high operating profit
AQ
2020C RAD : Web Presentation Interim Report Q3 2020
AQ
2020C RAD : Australian customers select C-RAD's cutting edge SIGRT solution
AQ
2020C RAD : Shanghai Proton and Heavy Ion Hospital decides for C-RAD SIGRT solution
AQ
2020C RAD : and Elekta expand cooperation - Elekta to distribute C-RAD's cutting-edg..
AQ
2020C RAD PUBL : Positive operating income in challenging times
AQ
2020C RAD PUBL : RAD Web Presentation Half-Year Report 2020
AQ
More news
Financials
Sales 2019 205 M 24,8 M 24,8 M
Net income 2019 -13,8 M -1,66 M -1,66 M
Net cash 2019 6,83 M 0,82 M 0,82 M
P/E ratio 2019 -98,9x
Yield 2019 -
Capitalization 1 599 M 193 M 193 M
EV / Sales 2018 4,12x
EV / Sales 2019 6,69x
Nbr of Employees 56
Free-Float 66,7%
Chart C-RAD AB (PUBL)
Duration : Period :
C-Rad AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C-RAD AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Tim Thurn President & Chief Executive Officer
Lars Gunnar Nyberg Chairman
Hakan Axelsson Chief Operating Officer
Henrik Bergentoft Chief Financial Officer
Peter Hamberg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
C-RAD AB (PUBL)-1.45%193
THERMO FISHER SCIENTIFIC10.48%203 954
DANAHER CORPORATION7.16%169 098
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.12.25%89 689
INTUITIVE SURGICAL, INC.-9.05%87 471
ILLUMINA, INC.9.80%59 313